Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Oct 29;8(6):zrae140.
doi: 10.1093/bjsopen/zrae140.

Inter-rater variability in multidisciplinary team meetings of oesophageal and gastro-oesophageal junction cancer on staging, resectability and treatment recommendation: national retrospective multicentre study

Affiliations
Multicenter Study

Inter-rater variability in multidisciplinary team meetings of oesophageal and gastro-oesophageal junction cancer on staging, resectability and treatment recommendation: national retrospective multicentre study

Christine Jestin Hannan et al. BJS Open. .

Abstract

Background: There are differences in oesophageal cancer care across Sweden. According to national guidelines, all patients should be offered equal care, planned and administrated by regional multidisciplinary team meetings. The aim of the study was to investigate differences between regional multidisciplinary team meetings in Sweden regarding clinical staging and treatment recommendations for oesophageal cancer patients.

Methods: All six Swedish regional multidisciplinary teams were each invited to retrospectively include ten consecutive oesophageal cancer cases. After anonymization, radiological investigations were presented, along with the original case-specific medical history, anew at the participating regional multidisciplinary team meetings. Estimation of clinical tumour node metastasis (TNM) classification and treatment recommendation (curative, palliative or best supportive care) were compared between multidisciplinary team meetings as well as with original assessments.

Results: Five multidisciplinary teams participated and contributed a total of 50 cases presented to each multidisciplinary team. In estimations of cT-stage, the multidisciplinary teams were in total agreement in only eight of 50 cases (16%). For cN-stage, total agreement was seen in 17 of 50 cases (34%) and for cM-stage there was agreement in 34 cases (68%). For cT-stage, the overall summarized κ value was 0.57. For N-stage and M-stage the κ values were 0.66 and 0.78 respectively. Differences in appraisal were not associated with usage of positron emission tomography-computed tomography. In 15 of 50 cases (30%) the multidisciplinary teams disagreed on curative or palliative treatment.

Conclusion: The study shows differences in assessment of clinical TNM classification and treatment recommendations made at regional multidisciplinary team meetings. Increased interrater agreement on clinical TNM classification and management plans are essential to achieve more equal care for oesophageal cancer patients in Sweden.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Evaluations of: a clinical T-stage, b clinical N-stage, c clinical M-stage with five new assessments and one original cT-, cN- and cM-stage appraisal on the y-axis and a total of 50 study cases on the x-axis, arranged with more severe stages to the right. White dot = missing value, grey dot = TX/NX/MX, purple dots = T0–T4b, pink dots = N0–N3, green dots = M0–M1. Darker colours indicate a higher T/N/M-stage. Original MDT highlighted with a thicker line. MDT, multidisciplinary team meetings; NA, not assessed.
Fig. 2
Fig. 2
Recommended treatment by MDT for study cases 1–50 Original MDT highlighted with a thicker line. MDT, multidisciplinary team meetings; NA, not assessed.

Similar articles

References

    1. Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev 2013;(5):CD008107. - PMC - PubMed
    1. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681–692 - PubMed
    1. Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol 2021;39:1995–2004 - PubMed
    1. Freeman RK, Van Woerkom JM, Vyverberg A, Ascioti AJ. The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with esophageal cancer. Ann Thorac Surg 2011;92:1239–1242; discussion 1243 - PubMed
    1. Kersten C, Cvancarova M, Mjåland S, Mjåland O. Does in-house availability of multidisciplinary teams increase survival in upper gastrointestinal-cancer? World J Gastrointest Oncol 2013;5:60–67 - PMC - PubMed

Publication types